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Abstract 
 
 Multiple Sclerosis (MS) is the most common cause of neurological disability in 
young adults. In this study, the animal model of MS, experimental autoimmune 
encephalomyelitis (EAE) was used in conjunction with tissue harvest techniques, flow 
cytometry and an ex vivo assay system in order to immunophenotype cellular infiltrate 
over the course of disease, study microglial activation, evaluate the ability of microglia 
to stimulate T-cells and to determine the effects of small molecule inhibitors on certain 
biochemical pathways.  This study demonstrates that CNS infiltrate kinetics mirror 
disease course and suggests that microglia be involved in antigen presentation and 
effector function during disease course.  
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Introduction 
 
Multiple Sclerosis is an immune-mediated inflammatory demyelinating disease 
of the central nervous system (CNS) charactized by mononuclear cellular infiltrate into 
brain parenchyma, gliosis, axonal loss and neurodegeneration.  The illness most 
commonly presents itself in young adults aged 20-40 and is most often characterized by 
relapses and remissions of neurological disturbance which are attributable to the acute 
development of plaques (Greenstein, 2006).  The relapsing and remitting phase of the 
disease is followed by a phase of continuous progression of disability in most patients 
(McDonald and Ron, 1999).  While clinical and pathological research have contributed 
much to the understanding of the disease process of MS, much more remains unknown.  
Studies into the mechanisms of disease will inform successful strategies for the target-
based treatment of MS to limit and repair damage (Compston and Coles, 2008). 
Clincal Course and Diagnosis 
 
The onset of MS is either optic neuritis, transverse myelitis or a brain-stem 
presentation in 85% of cases (Greenstein, 2006) which is known as the clinically isolated 
syndrome.  If white-matter abnormalities are detected by MRI at clinically unaffected 
sites in addition to one of these episodes, the chance of a second attack of 
demyelination occurring to fulfill the criteria for relapsing-remitting MS increases from 
50% at 2 years to 82% at 20 years (Compston and Coles, 2008).  Recovery from each 
episode, occurring erratically between 1-5 times per year, is only partial.  Over time, 
persistent symptoms accumulate.  Eventually, 65% of patients reach the secondary 
progressive stage, which typically begins around 40 years of age (Compston and Coles, 
2008).  Cases of children with MS have also occurred, usually in girls presenting with 
encephalopathy. In these cases, the secondary progressive stage takes longer to reach 
from disease onset than in adults although children with MS usually reach the secondary 
progressive stage at a younger age than most adults.  In 65% of cases, death can be 
attributed to the disease (Compston and Coles, 2008).   
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 There is no one test for MS and diagnosis is primarily clinical (McDonald and Ron, 
1999).  Few clinical symptoms are specifically linked to MS, but Lhermitte’s symptom (a 
sensation of electricity running down the limbs or spine when the neck is flexed) and the 
Uhthoff phenomenon (transient worsening of disease signs when core body 
temperature is elevated) are characteristic of the disease (Compston and Coles, 2008).  
Other symptoms include vertigo, diplopia, weakness in the limbs, cognitive impairment, 
bladder or bowel disturbances and fatigue unrelated to weakness (McDonald and Ron, 
1999).  In most cases, clinical evidence is sufficient for diagnosis, but when diagnosis is 
ambiguous, MRIs can be used to indicate paraclinical features of disease including 
abnormalities in white matter and radiological lesions.  In 90% of patients, oligoclonal 
bands after protein electrophoresis of cerebrospinal fluid can also be detected 
(Compston and Coles, 1999).   
Causes and Risk Factors 
 
The cause of MS involves environmental factors and genetic susceptibility.  MS 
occurs more frequently in temperate climates and is more common in regions 
populated by northern Europeans (Greenstein, 2006).  Moving from a high-risk area to a 
low-risk area during childhood is associated with a reduced risk-factor for MS, whereas a 
migration towards a high-risk area from a low-risk area is associated with an increased 
risk when compared to the population of origin (Compston and Coles, 2008).  A 
significant number of relapses are preceded by viral infections.  Patients with MS report 
being infected with measles, mumps, rubella and Epstien-Barr virus at later ages than do 
HLA-DR2 matched controls (Compston and Coles, 2008).  Multiple sclerosis is more 
common in females than in males (~2:1) (Greenstein, 2006) and has a familial 
recurrence rate of about 20% (Compston and Coles, 2008). 
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Pathological Physiology and Disease Mechanisms 
 
Many clinical and laboratory features of MS can be explained by the effects of 
demyelination on saltatory conduction (Compston and Coles, 2002).  The 
oligodendrocyte, a principal target of immune attack in MS, synthesizes and maintains 
the myelin sheath of up to 40 neighboring nerve axons in the CNS.  Axons are insulated 
by this myelin sheath needed for salutatory conduction.  From the nodes of Ranvier, the 
unmyelinated segments, voltage-gated sodium channels cluster and action potentials 
are propagated down the axons. 
It is believed that the disease process begins with an increased migration of T-cells 
across the blood-brain barrier (BBB).  This defect arises from regulatory pathogenesis 
which allows the cells to set up an immune response in the brain.  Particular sites of 
inflammation are dominated by CD8+ T-cells, causing plaques.  These cells secrete 
interleukins 17 and 22 which disrupt the human BBB, allowing penetration of these 
cells.  As T and B lymphocytes and macrophages accumulate in the CNS, pro-
inflammatory cytokines amplify the immune response through recruitment of naïve 
microglia.  Microglial cells are resident CNS leukocytes that take part in innate immunity 
and adaptive immune responses in the CNS tissue. When alerted to injury or disease, 
microglial cells are thought to assume an activated phenotype. This activated phenotype 
allows the cells to respond to tissue damage through proliferation, migration to site of 
injury, phagocytosis of cellular debris, or the release of cytokines or reactive oxygen 
species.  Contact is established between activated microglia and oligodendrocyte-myelin 
units and a lethal signal is delivered through cell surface bound tumour necrosis factor, 
TNF.  Lesions form and grow radially as focal brain inflammation fades into diffuse 
parenchymal microglial activation resulting in abnormalities in white matter. 
Shadow plaques are formed as remyelination occurs as oligodendrocyte precursors 
migrate in response to myelin loss to act as a source of cells with the potential to 
remyelinate  naked axons (Williams et al, 2007).  
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Management and Treatment 
 
 In many situations, the priority is to improve the quality of life by masking 
individual symptoms, though temporary improvement can be achieved at times with 
high-dose methyl prednisolone (Miller et al, 2000).  The efficacy of treatment varies 
with the stage of disease course.  Presently least contentious is the use of β interferons 
and copaxone (glatiramir acetate) in relapsing-remitting disease where the frequency of 
new episodes is reduced by about 30% (Ebers et al, 1998) with effects extending beyond 
two years of treatment (Duquette et al, 1995).  Mitoxantrone (an anthracenedione 
antineoplastic drug) could be more efficacious than the interferons, however toxic 
effects of the drug limit it to use only in more aggressive cases of MS (Le Page, 2008). 
Natalizumab (humanisec anti-α4 integrin) has been shown to reduce relapse rate by 
68% when given by monthly infusion.  This drug is licensed for monotherapy for severe 
relapsing-remitting disease (Polman, 2006). 
The EAE Model 
 
 EAE has proven its value since its development in the 1930’s at Rockefeller 
University.  With a pathology including demyelination, axonal damage and clinical 
events of relapsing and remitting paralysis, several models and variations of EAE have 
mimicked common features of MS. The use of experimental autoimmune 
encephalomyelitis led to the development of copaxone, mitoxantrone and natalizumab.  
Clues to the pathogenesis of MS and new potential biomarkers have also been 
discovered through the use of EAE-based research. Continuing research with this animal 
model has much potential for the discovery of new treatments and the greater 
understanding of disease mechanisms (Steinman and Zamvil, 2006). 
Objective of Project 
 
Despite the high potential for microglial cells to play an important role in CNS 
autoimmunity, very little is known about their contributions during autoimmune 
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disease, such as MS. In addition, it is not clear how microglial cells become activated or 
how they interact with T lymphocytes. In order to immunophenotype cellular infiltrate 
over the course of disease, study microglial activation, evaluate the ability of microglia 
to stimulate T cells, and evaluate the effects of small molecule inhibitors on certain 
biochemical pathways, the animal model of MS, experimental autoimmune 
encephalomyelitis (EAE) was used in conjunction with tissue harvest techniques, flow 
cytometry and an ex vivo assay system. 
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Methods 
 
Animals 
 
Inbred SJL/J mice, aged four weeks and older, were obtained from The Jackson 
Laboratory, Bar Harbor, ME.  SJL/J mice were used for their susceptibility to 
experimental autoimmune encephalomyelitis. All animals were given food and water ad 
libitum and maintained on a twelve-hour light/dark cycle in the Abbott Bioresearch 
Center’s Department of Bioresources, Association for Assessment and Accreditation of 
Laboratory Animal Care (AAALAC) approved facility.  All animal care was in accordance 
with the National Institutes of Health guidelines. 
 
Induction of EAE and Disease Progression 
 
SJL/J mice were immunized subcutaneously with an emulsion containing 100g 
of PLP 139-151 (New England Peptide, Inc., Gardner, MA) and complete Freund’s 
adjuvant (CFA) containing 100g of heat-killed Mycobacterium tuberculosis H37Ra 
(Difco, Detroit, MI) over two hind limb sites and one scruff of neck site on Day 0. The 
mice were given an intraperitoneal injection with 60ng of Bordatella pertussis toxin (List 
Biological Laboratories, Campbell,CA) on the same day as immunization. The mice were 
weighed and assessed daily beginning on Day 7 for signs of EAE according to the 
following scale; 0, no signs of disease; 1, loss of tail tone; 2, moderate hindlimb 
weakness or irregular gait; 3, partial hind limb paralysis; 4, complete hind limb paralysis; 
5, moribund condition. 
 
Isolation of infiltrating leukocytes and microglia from the CNS   
 
On Days 0, 7, 13, 19 and 25 (Figure 1), five animals were anesthetized with 
isofluorane, terminally bled via cardiac puncture, and perfused with 10-20ml of 
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phosphate buffered solution (PBS) at pH 7.4 by insertion of a 25g needle into the left 
ventricle of the heart until effluent ran clear.  Brain and spinal cord were harvested in 
cold PBS on ice and finely minced before being covered with a digestion mixture 
containing Liberase RI (Roche, Germany) at 0.2 Wunsch Units/10ml, 50g/ml Dnase I 
(Roche, Germany), 25mM Hepes (Invitrogen, Carlsbad, CA) in Hanks’ Balanced Salt 
Solution without Magnesium Chloride or Calcium Chloride (Invitrogen, Carlsbad, CA) for 
30mins at 37C.  A single cell suspension was generated by pushing CNS through a BD 
Falcon cell strainer in a cold rinsing buffer containing Hanks’ Balanced Salt Solution 
without Magnesium Chloride or Calcium Chloride (Invitrogen, Carlsbad, CA) and 2mM 
EDTA. Cells were pooled and collected in a 50ml tube then centrifuged at 313xg for ten 
minutes. The pellet was re-suspended in 16.6ml of 1X PIPES Buffer (Sigma, St. Louis, 
MO) and 7.2mls of 100% Percoll (Sigma, St.Louis, MO) was added.  Cells were layered 
carefully over 2.55ml of 65% Percoll in 1X PIPES in two 15ml conical tubes which were 
centrifuged at 514xg at room temperature for thirty minutes, no brake.  Before 
collecting the cells of interest, the top 1ml containing CNS matrix tissue was removed 
and 9mls of Percoll were removed. The cells at the 65%/30% interface in each 15ml tube 
were pooled into another 15ml tube.  The tube was then filled with Hanks’ Balanced Salt 
Solution without Magnesium Chloride or Calcium Chloride to dilute and wash out the 
Percoll and tubes were centrifuged at 313xg for 10 minutes. The supernatant was 
removed and the pellet was re-suspended again in Hanks’ Balanced Salt Solution 
without Magnesium Chloride or Calcium Chloride and centrifuged at 313xg for 10 
minutes again to wash the cells. Cells were then counted and re-suspended in 150l 
FACS Buffer (FB, 1x PBS + 2% v/v FBS + 0.2% w/v Na azide). Cells were placed in 96 well 
plates at 30l per well and non-specific Fc binding was blocked with 30l Mouse BD Fc 
Block (Pharmingen, San Diego, CA).  After incubating with the blocking agent for 30 
minutes on ice, the cells were stained with cell surface markers for CD45, CD11b, CD11c, 
MHC II, CD80, CD40, CD34 for 30 minutes, covered, on ice (Table 1).  Appropriate 
isotype controls were used to define staining above background.  The cells were then 
washed three times with FB and analyzed on the FACSCaliber (BD, San Diego, CA). 
11 
 
 
Cell sorting and ex vivo assay protocol 
 
 Brain and spinal cord tissues were harvested from diseased animals on Day 13. 
Tissues were processed and layered to collect a single cell suspension as described in 
the Isolation of infiltrating leukocytes and microglia from the CNS protocol.  Cells were 
then counted and resuspended in 1ml FB, blocked with Mouse BD Fc Block (Pharmingen, 
San Diego, CA) and stained with CD11b following a 30 minute incubation on ice. After 
staining, the cells were washed and re-suspended in 1ml of Robosep Buffer.  Cells were 
separated using the EasySep (StemCell Technologies, Vancouver, BC, Canada) procedure 
for phycoerythrin- (PE) selection.  
 Lymph nodes were harvested from PLP-immunized animals.  The lymph nodes 
were processed to single cell suspensions by grinding them between the frosted ends of 
slides.  CD4+ T-cells were separated with Robosep Selection (StemCell Technologies, 
Vancouver, BC, Canada). 
 CD11b+ microglia and monocytes were plated at 2x105 cells per well. CD4+ T-
cells were plated at 3x105 cells per well.  CD11b+ cells were plated alone, with PLP-
primed T-cells, T-cells and PLP, T-cells, PLP and Compound A at 1µM and T-cells, PLP, 
and FTY at 100nM.  Supernatant was collected for TNF, IFN-γ, and IL-17 levels. 
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Results 
 
CNS Infiltrate Kinetics 
 
Immunized animals used for CNS harvesting on Days 0, 7, 13, and 25 had average 
clinical scores throughout disease course and a typical relapsing-remitting trend of 
disease scores (Figure 2).  Figure 2 shows the average total CNS cell count per animal 
determined by pooling five animals at each time point. 
FACS plots of naïve animals (Day 0) and Day 13 animals, as seen in Figure 3, show 
a forward and side scatter of CD45 and CD11b. CD45 med, CD11b+ cells are microglia. 
CD45hi, CD11b- cells are infiltrating T-cells. CD45hi, CD11b+ cells are monocytes.  
Although the percentage of resident microglia decreases from 83.3% to 50.7% between 
naïve and diseased animals, the total cell count rises substantially from 2.4x106 to 
8.8x106, and so the total number of cells expressing a microglial phenotype doubles 
from 2.0x106 cells to 4.5x106. This data can be more clearly seen in Figure 4, which 
shows the average cell count per animal at each time point (n=5 pooled) for microglia, 
infiltrating T-cells, infiltrating monocytes and dendritic cells.  All cell types follow the 
same general trend over disease course, but the baseline microglial cell number is much 
higher due to resident microglial cells in naïve CNS. 
Activation States of Microglia 
 
 Though CD40 and MHC II cell markers were used to identify activated microglia, 
no staining was found with either of these markers. CD34 also did not show staining for 
microglial progenitor cells.  
 CD80 was also used to identify activated microglia, as seen in Figure 5.  Figure 5 
shows the FACS plots of Day 7 and Day 13 diseased animals with CD45 and CD80 
staining. CD45med, CD80+ cells are activated microglia. This population percentage 
increased from Day 7, 4.12%, to Day 13, 40.1%.  These percentages are of the total 
number of microglia at each of these days (n=5 pooled). 
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Microglia and T-cell Assay 
 
 Figure 6 shows the cytokine levels resulting from the assay with microglia from 
diseased animals and PLP-primed T-cells.  Microglia were plated alone, with T-cells, with 
T-cells and PLP, with T-cells, PLP, and Compound A at 1µM, and with T-cells, PLP, and 
FTY at 100nM.  There is no change in cytokine levels resulting from microglia plated 
alone and microglia plated with T-cells. When microglia are plated with T-cells and PLP, 
IFN-γ and IL-17 levels rise while TNF levels remain consistent.  When Compound A is 
added, IFN-γ levels decrease significantly. 
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Discussion 
Interpreting Experimental Results 
 
 Immunophenotyping of CNS in diseased animals showed CNS infiltrate kinetics 
mirror disease course.  T cell, dendritic cell, and macrophage numbers increased 
through peak disease (Day 13), decreased during remitting phase of disease (Day 19) 
and increased during relapse (Day 25).  Microglial counts also increased from baseline 
resident numbers during peak disease and relapse due to proliferation of resident 
progenitor cells or infiltrating monocytes differentiating into microglial phenotype. 
 When microglia become alerted to tissue damage in the CNS, the cells take on an 
activated phenotype which allows for proliferation,  migration to site of injury or the 
release of cytokines.  In the course of EAE, microglia in the CNS take on an activated 
phenotype between Day 7 (disease onset) and Day 13 (peak disease). 
Microglia and T-cell assays show that microglia may act as APCs during 
autoimmune disease.  Treatment with Compound A significantly reduced IFN-γ 
production after PLP stimulation, indicating that this assay may be a viable tool to 
evaluate the effects of small molecule inhibitors on various biochemical pathways 
through their effects on microglial function. 
The increase in microglial cell numbers, the activation of microglia at peak 
disease and the ability of microglia to act as APCs in disease signify that microglia may 
have a substantial role in a variety of pathological conditions in the CNS, including MS.  
Though disease mechanisms are still not fully understood, microglia may be a target for 
drug development to limit and repair CNS damage in MS.  
Future Directions  
 
Further investigation into the roles that microglia play in disease are crucial in 
understanding disease mechanisms.  Repeat CNS infiltrate kinetics studies should be 
conducted to confirm results and specific work with different cell markers, including 
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CD40 and MHC II in CNS infiltrate kinetics should be conducted to verify the activation of 
microglia over disease course.   
The ex vivo microglia and T-cell assay system should be further optimized and 
utilized to study small molecule inhibitors through their effects on microglial function.  
Dose response studies should be conducted with these compounds to detect any 
significant changes in cytokine production levels. 
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Tables and Figures 
Table 1: List of Cell Markers 
Cell marker Catalog Number Specificity Antibody Vendor 
CD45 553064 Hematopoietic cells 
 
Pharmingen 
CD11b 553311 Monocytes, 
Macrophages    
 
Pharmingen 
CD11c 550261 Dendritic cells 
 
Pharmingen 
MHC II 553536 Monocytes, 
Macrophages, Dendritic 
cells, Activated 
microglia 
 
ebioscience 
CD80 553768 Activated monocytes, 
Macrophages, Dendritic 
cells 
Pharmingen 
CD34 560238 Microglia progenitor 
cells 
Pharmingen 
CD40 553790 Activated microglia Pharmingen 
Mouse BD Fc Block 553142 Blocking agent Pharmingen 
 
Figure 1: CNS Harvesting Time Points through Typical PLP-induced 
EAE Disease Course (SEM Error Bars shown) 
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Figure 2: Cell counts in the CNS and their correlation with clinical 
signs of EAE (SEM Error Bars shown) n=5/time point 
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Figure 3: FACS plots of Naïve and Day 13 Diseased CNS (CD45 stains 
hematopoietic cell, CD11b stains monocytes and macrophages) 
  
 
 
Figure 4: CNS Infiltrate Kinetics (n=5/time point) 
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Figure 5: Activation States of Microglia in EAE Disease Course (CD45 
stains all hematopoietic cells and CD80 stains activated monocytes 
and macrophages) 
 
 
Figure 6: Microglia and T-cell Assay 
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